Fellow Eye Effect of Unilateral Intravitreal Bevacizumab Injection in Eyes with Diabetic Macular Edema

Overview

Journal Eye (Lond)

Specialty Ophthalmology

Date 2014 May 27

PMID 24858528

Citations 28

Authors

J Hanhart

L Tiosano

E Averbukh

E Banin

I Hemo

I Chowers

Affiliations

Soon will be listed here.

Abstract

Aims: Anti-vascular endothelial growth factor compounds are routinely used for the treatment of diabetic macular edema (DME). We aim to evaluate for the existence and magnitude of treatment effect on fellow un-injected eyes.

Methods: A consecutive group of patients with bilateral DME who received unilateral bevacizumab injections was retrospectively evaluated. Data collected included demographics, ophthalmic and systemic findings, and optical coherence tomography (OCT) measurements of macular thickness.

Results: Thirty-five patients were evaluated. Mean follow-up was 245 days (range: 30-800), and the mean number of bevacizumab injections was 3.6 (range: 1-11). At end of follow-up, the mean (SD) OCT central subfield thickness reduced by 72 ± 112 micron in the injected eye (from 469 ± 139 to 397 ± 120 micron; P=0.001), while in the non-injected eye it reduced by 49 ± 75 micron (from 380 ± 130 to 331 ± 106 micron; P<0.001). Sixteen injected eyes (45.7%) showed central subfield thickness reduction of ≥50 micron while 10 (28.6%) non-injected eyes showed such thickness reduction. Improved VA following treatment was detected in 14 (40%) injected eyes and in 15 (43%) non-injected eyes.

Conclusions: Unilateral bevacizumab injections in patients with bilateral DME are often associated with bilateral response.

Summary Statement: Anti-vascular endothelial growth factor compounds are routinely used for the treatment of diabetic macular edema (DME). In this retrospective study, we show that unilateral bevacizumab injections often result in reduction of the macular thickness in the fellow un-injected eye.

Citing Articles

Evaluating the Effects of C3 Inhibition on Geographic Atrophy Progression from Deep-Learning OCT Quantification: A Split-Person Study.

Fu D, Lipkova V, Liefers B, Glinton S, Faes L, McKeown A Ophthalmol Ther. 2023; 12(6):3143-3158.

PMID: 37715860 PMC: 10640460. DOI: 10.1007/s40123-023-00798-7.

Ocular stress enhances contralateral transfer of lenadogene nolparvovec gene therapy through astrocyte networks.

McGrady N, Boal A, Risner M, Taiel M, Sahel J, Calkins D Mol Ther. 2023; 31(7):2005-2013.

PMID: 37016579 PMC: 10362393. DOI: 10.1016/j.ymthe.2023.03.035.

Relationship Between Macular Thickness and Visual Acuity in the Treatment of Diabetic Macular Edema With Anti-VEGF Therapy: Systematic Review.

Wang P, Hu Z, Hou M, Norman P, Chin E, Almeida D J Vitreoretin Dis. 2023; 7(1):57-64.

PMID: 37008395 PMC: 9954155. DOI: 10.1177/24741264221138722.

Case Report: A Case of Cystoid Macular Edema in Retinitis Pigmentosa With Central Retinal Vein Occlusion.

Wang D, Gu C, Yuan Y Front Med (Lausanne). 2022; 9:877429.

PMID: 35755060 PMC: 9218176. DOI: 10.3389/fmed.2022.877429.

Interleaved Optical Coherence Tomography: Clinical and Laboratory Biomarkers in Patients with Diabetic Macular Edema.

Suciu C, Suciu V, Cutas A, Nicoara S J Pers Med. 2022; 12(5).

PMID: 35629188 PMC: 9147367. DOI: 10.3390/jpm12050765.

References

Sinapis C, Routsias J, Sinapis A, Sinapis D, Agrogiannis G, Pantopoulou A . Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits. Clin Ophthalmol. 2011; 5:697-704. PMC: 3104800. DOI: 10.2147/OPTH.S19555. View

Acharya N, Sittivarakul W, Qian Y, Hong K, Lee S . Bilateral effect of unilateral ranibizumab in patients with uveitis-related macular edema. Retina. 2011; 31(9):1871-6. DOI: 10.1097/IAE.0b013e318213da43. View

Wu Z, Sadda S . Effects on the contralateral eye after intravitreal bevacizumab and ranibizumab injections: a case report. Ann Acad Med Singap. 2008; 37(7):591-3. View

Matsuyama K, Ogata N, Matsuoka M, Wada M, Takahashi K, Nishimura T . Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol. 2010; 94(9):1215-8. DOI: 10.1136/bjo.2008.156810. View

Scartozzi R, Chao J, Walsh A, Eliott D . Bilateral improvement of persistent diffuse diabetic macular oedema after unilateral intravitreal bevacizumab (Avastin) injection. Eye (Lond). 2008; 23(5):1229. DOI: 10.1038/eye.2008.162. View

Aiello L, Beck R, Bressler N, Browning D, Chalam K, Davis M . Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. Ophthalmology. 2011; 118(12):e5-14. PMC: 3253487. DOI: 10.1016/j.ophtha.2011.09.058. View

Avery R, Pearlman J, Pieramici D, Rabena M, Castellarin A, Nasir M . Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006; 113(10):1695.e1-15. DOI: 10.1016/j.ophtha.2006.05.064. View

Wang H, Sun X, Liu K, Xu X . Intravitreal ranibizumab (lucentis) for the treatment of diabetic macular edema: a systematic review and meta-analysis of randomized clinical control trials. Curr Eye Res. 2012; 37(8):661-70. DOI: 10.3109/02713683.2012.675616. View

Elman M, Bressler N, Qin H, Beck R, Ferris 3rd F, Friedman S . Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011; 118(4):609-14. PMC: 3096445. DOI: 10.1016/j.ophtha.2010.12.033. View

10.

Nguyen Q, Brown D, Marcus D, Boyer D, Patel S, Feiner L . Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012; 119(4):789-801. DOI: 10.1016/j.ophtha.2011.12.039. View

11.

Bakri S, Snyder M, Reid J, Pulido J, Ezzat M, Singh R . Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007; 114(12):2179-82. DOI: 10.1016/j.ophtha.2007.09.012. View

12.

Meyer C, Krohne T, Holz F . Concentrations of unbound bevacizumab in the aqueous of untreated fellow eyes after a single intravitreal injection in humans. Acta Ophthalmol. 2010; 90(1):68-70. DOI: 10.1111/j.1755-3768.2009.01842.x. View

13.

Velez-Montoya R, Fromow-Guerra J, Burgos O, Landers 3rd M, Morales-Caton V, Quiroz-Mercado H . The effect of unilateral intravitreal bevacizumab (avastin), in the treatment of diffuse bilateral diabetic macular edema: a pilot study. Retina. 2008; 29(1):20-6. DOI: 10.1097/IAE.0b013e318186c64e. View

14.

Nomoto H, Shiraga F, Kuno N, Kimura E, Fujii S, Shinomiya K . Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci. 2009; 50(10):4807-13. DOI: 10.1167/iovs.08-3148. View

15.

Chakravarthy U, Harding S, Rogers C, Downes S, Lotery A, Wordsworth S . Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012; 119(7):1399-411. DOI: 10.1016/j.ophtha.2012.04.015. View

16.

Al-Dhibi H, Khan A . Bilateral response following unilateral intravitreal bevacizumab injection in a child with uveitic cystoid macular edema. J AAPOS. 2009; 13(4):400-2. DOI: 10.1016/j.jaapos.2009.03.006. View

17.

Mitchell P, Bandello F, Schmidt-Erfurth U, Lang G, Massin P, Schlingemann R . The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011; 118(4):615-25. DOI: 10.1016/j.ophtha.2011.01.031. View

18.

Kook D, Wolf A, Kreutzer T, Neubauer A, Strauss R, Ulbig M . Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Retina. 2008; 28(8):1053-60. DOI: 10.1097/IAE.0b013e318176de48. View

19.

Bakbak B, Ozturk B, Gonul S, Yilmaz M, Gedik S . Comparison of the effect of unilateral intravitreal bevacizumab and ranibizumab injection on diabetic macular edema of the fellow eye. J Ocul Pharmacol Ther. 2013; 29(8):728-32. DOI: 10.1089/jop.2013.0049. View

20.

Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C . Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol. 2011; 153(2):327-333.e1. DOI: 10.1016/j.ajo.2011.07.005. View